Cingulate INC 10-Q quarterly reports

Cingulate Inc. reported a significant increase in operating expenses and net loss for the six months ended June 30, 2026, alongside a Complete Response Letter from the FDA for its lead drug candidate, CTx-1301.

Cingulate Inc. reported a net loss of $9.3 million for Q1 2026, with significant increases in general and administrative expenses, while maintaining sufficient cash for operations into early 2027.

Cingulate Inc. reported a significantly wider net loss in Q3 2025 as R&D and administrative expenses surged, while its lead ADHD drug CTx-1301 advanced to FDA review despite ongoing liquidity concerns and recent management turmoil.

Cingulate Inc. reported increased net losses and a going concern warning, while successfully submitting its lead ADHD drug NDA and undergoing significant management restructuring.

Cingulate Inc. announces its financial results for the first quarter of 2025, highlighting ongoing development of its ADHD and anxiety treatments and providing a business update.

Cingulate Inc. announced its third quarter 2024 financial results, highlighting progress in clinical development and strategic financial activities.

Cingulate Inc. reported its financial results for the second quarter of 2024, highlighting a decrease in operating expenses and providing updates on its clinical programs and recent capital raising activities.

Cingulate Inc. reported a net loss of $2.97 million for the first quarter of 2024, while also providing updates on its clinical programs and financial activities.